Description
The global Positive Allosteric Modulator market was valued at USD 1,651.5 million in 2021 and is projected to hit around USD 2,911.3 million by 2028, expected to grow at a compound annual growth rate (CAGR) of 8.3% from 2022 to 2028. Allosteric modulators bind to a receptor and change their response to a stimulus. Positive allosteric modulators aid Agonist-mediated responses. Positive allosteric modulators are employed as a unique therapy strategy for patients with mental diseases such as dementia, schizophrenia, and others, estimated to drive the global market. Patients can be given positive allosteric modulators in combination with their existing approved anti-AD medicines to boost the efficacy of the drugs. In addition, the market is expected to expand primarily due to the rising number of cases of Alzheimer’s disease.
